STAT

DECEMBER 17, 2023

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021. Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive.

133

133

pharmaphorum

DECEMBER 17, 2023

Bristol-Myers Squibb has abandoned a bid to extend the indications of its combination of PD-1 inhibitor Opdivo and LAG-3 inhibitor relatlimab into colorectal cancer after it failed the phase 3 RELATIVITY-123 trial.

109

109

STAT

DECEMBER 17, 2023

Every year, the health care industry behaves more and more like a balloon: Squeeze one side, and the other expands. Companies that were once just insurers or just pharmacies are tacking on new business lines. The idea is that when profit inevitably gets squeezed in one, it’ll expand in another. That trend of vertical integration was on full display in 2023, a year when the country’s biggest pharmacy chain bought a primary care provider, and the biggest private insurer branched furt

Insurance 123

Insurance Hospitals 123

Med Ed 101

DECEMBER 17, 2023

Semaglutide products have been popping up in news headlines recently, and not because of their continued popularity as effective weight loss medications. Data from poison control centers across the country indicates a drastic increase over the past year in calls related to semaglutide overdose — an increase of over 1500% since 2019 according to a […] The post Semaglutide Overdose – What Does It Look Like and Why Is It Happening?

105

105

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

The Guardian - Pharmaceutical Industry

DECEMBER 17, 2023

Veoza, also known as fezolinetant, is prescription-only and will be available privately from January A “gamechanging” drug that prevents hot flushes and could benefit hundreds of thousands of women has been approved for use in the UK. The green light for Veoza, also known as fezolinetant, comes after the US regulator, the Food and Drug Administration, authorised it for use in America in May.

105

105

The Guardian - Pharmaceutical Industry

DECEMBER 17, 2023

Health bosses condemn ‘irresponsible’ targeting of people desperate for NHS help Wellness firms are exploiting a national shortage of ADHD medication to push so-called “smart supplements” as an alternative to prescribed drugs. As patients struggle to get hold of medication – or face years-long waits for NHS assessments – companies are peddling unproved products as a “natural” treatment for attention deficit hyperactivity disorder.

80

80